loader
Please Wait
Applying Filters...

Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    List of Drug Master Files (DMF) for 20682 Active Pharmaceutical Ingredient (API) submitted to the U.S. FDA. Original Data : FDA Website

    Client Virtual Booth
    Menu

    Purisys LLC

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    PharmaCompass Sponsored Ads

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Left Arrow
    Right Arrow
    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 Purisys LLC (1)

    filter

    01 DRONABINOL DRUG SUBSTANCE IN SESAME OIL (1)

    filter

    01 U.S.A (1)

    filter

    01 Active (1)

    filter

    01 Complete (1)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us

    PURISYS LLC

    Contact Supplier
    • FDA
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    DRONABINOL DRUG SUBSTANCE IN SESAME OIL

    PDF Supplier PDF
    URL Supplier Web Content
    20682
    Active
    2007-07-16
    Complete
    2022-06-28
    2022-06-23
    II
    Noramco

    Iran Expo

    Not Confirmed

    envelop Contact Supplier

    Looking for Drug Master Files (DMF) for 20682 of Purisys Llc

    Looking for Drug Master Files (DMF) for 20682 of Purisys Llc 1

    20

    Purisys Llc, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA.

    One of their notable products is DRONABINOL DRUG SUBSTANCE IN SESAME OIL, with a corresponding US DMF Number 20682.

    Remarkably, this DMF maintains an Active status since its submission on July 16, 2007, highlighting commitment to regulatory compliance.

    Their GDUFA DMF Review was successfully complete, with a review date of June 28, 2022, and payment made on June 23, 2022, indicating their dedication to facilitating drug approvals, Categorized as Type II

    Post Enquiry
    POST ENQUIRY